Category: Technology Licenses
Created On: 2022-04-28
Record Count: 18
- Drug Discovery
- Viral Infection
- HIV / AIDs
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 305251
Premas vaccine platform is certain patent applications, know-how and other proprietary information related to a vaccine platform that involves genetically engineered and modified yeast, Saccharomyces cerevisiae, which along with certain proprietary expression vectors and optimized genes developed to be used with the above strain, and, has been shown to be useful in the expression of more than thirty type 1 endoplasmic reticulum associated proteins.
IPSCIO Record ID: 298360
Licensor is is a clinical-stage biopharmaceutical company with expertise in the pre-clinical and clinical development of pharmaceutical products.
Licensed Product means products and services that are made, made for, used, imported, offered for sale or sold by Company or its Affiliates or sublicensees in the field.
â€¢VaxCelerate offers two unique elements to combat the Coronavirus – one fixed immune adjuvant and one variable immune targeting and offers several potential advantages over other compounds in combination therapy.
The vaccine focuses on both DNA and internal/external mutated proteins providing the immune system with more potential targets to attack.
Field shall mean all products and processes or uses developed hereunder, whether or not related to the Patent Rights, for the prevention, interception or treatment of COVID-19 and other related corona viruses, or otherwise.
IPSCIO Record ID: 340468
Licensor will grant to Licensee an exclusive, worldwide license under Licensors rights in certain patents and related intellectual property, or the License, in which Licensee will receive certain rights relating to Licensorâ€™s proprietary oral delivery technology to further develop, manufacture and commercialize oral vaccines for COVID-19 and other novel coronaviruses based on proprietary vaccine technology involving a triple antigen virus like particle, or the Product.
Licensed IP means Patent Rights, Know-How and Information related to Licensorâ€™s proprietary PODTM oral delivery technology involving a triple antigen virus like particle, or the Product.
The oral COVID-19 vaccine being developed promoted both systemic immunity through Immunoglobulin G (IgG), the most common antibody in blood and bodily fluids that protects against viral infections, and Immunoglobulin A (IgA).
Licensee is focused on the development of novel oral COVID-19 vaccines based on Licensorâ€™s proprietary PODTM oral delivery technology as well as novel vaccine technology that was previously assigned to Licensee.
IPSCIO Record ID: 305790
Licensor is a clinical stage, publicly-traded drug discovery, development and manufacturing company using precise protein engineering and rational design (enabled by Licensors proprietary XpressCF platform technology) to advance next-generation oncology therapeutics.
The primary invention underpinning the XpressCF platform was the creation of engineered E.coli-derived proprietary extracts containing fully functional oxidative phosphorylation machinery in inverted membrane vesicles and orthogonal tRNA capable of catalyzing nnAA incorporation. This innovation enables the Extract to regenerate high energy phosphates required for protein translation and nnAA incorporation, reducing production cost and permitting the use of industrial sized reaction vessels and longer manufacturing run times than previously thought possible. The XpressCF system routinely produces g/L of complex proteins in 8-10 hours and scales linearly from bench to large-scale GMP production. The protein of interest is produced at high yield and the absence of cellular debris combine to simplify downstream purification, further enhancing production efficiency.
XpressCFâ„¢, an industrialized cell-free protein synthesis platform, for the vaccine field allowing (1) site-specific conjugation; (2) production of complex antigens in more optimal conformation; and (3) speed, flexibility and scalability of the discovery engine.
The XpressCF platform overcomes these significant limitations by separating the precise cellular machinery required for transcription, translation, and energy production into an E.coli-derived mixture, or Extract capable of continuous oxidative phosphorylation.
Licensee is a next-generation vaccine company whose cell-free protein synthesis platform enables the design and production of optimized protein carriers and antigens, the critical building blocks of vaccines.
IPSCIO Record ID: 297935
Under a license from Licensor, Licensee has right to use the XpressCFÂ® and XpressCF+â„¢ platforms to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases.
XpressCFÂ® – integrated cell-free protein synthesis platform
XpressCF+â„¢ – site-specific conjugation platform
Both of these platforms allow to rapidly and precisely create optimally designed, next-generation protein therapeutics candidates.
The platform represents a major advancement over conventional conjugate vaccine production methods, by enabling precise and consistent conjugation of antigens to site-specific locations on a protein carrier that do not impede T-cell help resulting in higher-potency conjugates.
IPSCIO Record ID: 379884
An exclusive license under the Patents to (a) Develop, make, lease, sell, license, or otherwise distribute Products; and (b) Practice the Processes solely as necessary for the exercise of the foregoing rights.
A non-exclusive limited license to use and copy the Technology internally solely as necessary for the use or practice of the Patents. Hospital will deliver a copy of the Technology to Licensee at a time mutually agreed to by the parties and will have no obligation to update the Technology at any later period.
U.S. Patent 9,096,644, entitled â€œAntigen-Norovirus P-Domain Monomers and Dimers, Antigen-Norovirus P-Particle Molecules, and Methods of Their Making and Useâ€, filed on Jun. 9, 2009, with a priority date of Jul. 10, 2009.
US Patent No 9,562,077, entitled â€œProtein Complex System for Increased Immunogenicity and Functionality, and Methods Making and Useâ€, filed on Mar. 14, 2013, with priority date July 11, 2012 (Provisional Application No. 61/670,288).
IPSCIO Record ID: 308732
The College grants to Licensee a non-exclusive, worldwide, license under its rights in and to the College Technology Transfer Materials solely for use in identifying, discovering, developing, making, having made, using, marketing, offering for sale, selling, having sold and importing any Type I Licensed Product or Type II Licensed Product.
Type I Licensed Product shall mean any product, the manufacture, use, sale, marketing or importation of which falls within the scope of a Valid Claim in the country in which it is manufactured, used, sold, marketed or imported. Type II Licensed Product' shall mean any product that is not a Type I Licensed Product, but is identified or discovered through the use of a Licensed Method.
Licensed Services shall mean any service provided for or on behalf of a third party on a fee-for-service basis that entails the practice of a Licensed Method.
Materials transferred include
– Chlamydia libraries (donor library and expression library with and without cLLO)
– pDEST-SL8 expression vector
– Plasmids and E. Coli Strains
– T cell Lines
– Other Cell Lines, and,
– Protocols as follows
1. Gateway cloning
2. CE6 phage prep
3. Library induction
4. Library screening
5. Chlamydia growth and prep
6. T cell expansion (multiple protocols)
7. APC preps
8. Chlamydia infection ( cell line and mouse)
9. B3Z assay for library validation
10. ICS assay for antigen presentation
Chlamydia, or more specifically a chlamydia infection, is a sexually transmitted infection caused by the bacterium Chlamydia trachomatis.
Licensee is a clinical stage biotechnology company that discovers and develops novel vaccines to address infectious diseases for which no vaccine or vaccines with limited effectiveness exist today.
IPSCIO Record ID: 263928
IPSCIO Record ID: 307944
Licensee is an affiliate of the China Technology Exchange, and is enabling the development of the COVID-19 vaccine in China.
IPSCIO Record ID: 230788
Food Safety Product means a Product to eliminate or reduce organisms associated with food borne disease in livestock.
The licensed property include patents for Immunogenic compositions comprising avirulent derivatives of Salmonella typhi with mutations in cya, crp and cdt, Method of maintaining a desired recombinant gene in a genetic population of cells, Avirulent Salmonella containing genes encoding gamete specific antigen useful as vaccine for diminishing or preventing fertility, Method of vaccination of newly hatched poultry, Recombinant vaccines comprising immunogenic attenuated bacteria having RpoS phenotype, Methods of producing and using virulence attenuated poxRmutant bacteria, Recombinant bacterial system with environmentally limited viability, Live attenuated Salmonella vaccines to control avian pathogens, Regulated Antigen Delivery Systems, and, various patents for Avirulent microbes.
IPSCIO Record ID: 306663
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 is the strain of coronavirus that causes coronavirus disease 2019 (COVID-19), the respiratory illness responsible for the COVID-19 pandemic.
IPSCIO Record ID: 279292
For the Trademarks for Licensed Products. To the extent that Licensor owns any Trademark(s) that pertain specifically to a Licensed Vaccine or Licensed Product, Licensor grants an exclusive right and license, with the right to grant sublicenses to Trademark(s) Controlled by Licensor solely for use with respect to such Licensed Vaccine or Licensed Product, as the case may be.
Licensor has rights under certain patent rights and know-how rights relating to Tarmogens.
Licensed Product means any product in final form that contains a Licensed Vaccine as a therapeutically or prophylactically active ingredient.
Combination Product means any product sold in a particular country that contains a Licensed Vaccine in combination with one (1) or more other therapeutically active ingredients or drug delivery technology, devices, equipment or other components, as applicable, or formulated or packaged separately but sold together for a single price.
The Field means, any and all human diseases and conditions, except the treatment of any malignancy; provided, however, that Field shall include [the treatment, palliation, diagnosis and/or prevention of hepatitis that may result in the prevention and/or reduction in frequency and incidence of any and all sequelae of hepatitis infection, including the prevention and/or reduction in the frequency and incidence of hepatocellular carcinoma in patients who have co-existing hepatocellular carcinoma.
IPSCIO Record ID: 371191
Epitopes or protein of antigens which can be utilized to develop singular or multi-targeted vaccines. Epitopes can simply be fused to the end of the S domain via flexible linker through recombinant DNA technology. Identified epitopes of limited variability in H1 influenza that have circulated throughout history (since 1918) and make ideal vaccine targets and have completed similar analysis of H3 and Flu B strains for similar epitopes which will be used to produce our lead vaccine candidate BWV-101 as a universal vaccine for influenza infection. Due to the cross-reactive nature of the H1 epitopes in pre-pandemic H1 influenza A, companies are pursuing the development of a stand-alone H1 vaccine (BWV-102). These epitopes are able to be formulated into a vaccine candidate using the VLP platform technologies and may be evaluated using other vaccine technologies through partnerships in order to accelerate development of potential vaccines or to explore adjunct therapies.
Field of use is for the treatment of influenza.
IPSCIO Record ID: 308731
Licensor, a non-profit health care organization, grants to Licensee, under Licensors one-half ownership interest in the Patent Rights, subject to the rights granted under a separate Party License, the worldwide right and exclusive license, with the right to sublicense, to import. make, have made, use, lease, offer for sale, sell and otherwise export the Licensed Products, and to practice the Licensed Processes, in the Territory for the Field of Use during the Term, unless sooner terminated as provided in this Agreement.
The patent applications include 61/221,541; 61/240,616; 61/316,267; 12/826,084; 61/434,818; 13/355,468; 61/589,267; and, 61/609,171.
Streptococcus pneumoniae (pneumococcus) is a Gram-positive bacterium that is responsible for the majority of community-acquired pneumonia. It is a commensal organism in the human respiratory tract, meaning that it benefits from the human body, without harming it
Licensee has rights to Patt Vaccine Sustems that include a non-exclusive right to sublicense, to develop, make or have made, and use a pneumococcal T cell based protein vaccine in the world and (ii) use market, promote, distribute and sell a pneumococcal T cell-based protein vaccine in Developing Countries.
Licensee has developed and/or controls a high-throughput system for in vitro screening of proven effectors of immunity ( e.g. libraries of efficacious T cells) to identify their specific target antigens from the complete proteome of any disease-causing agent, the High Throughput System. It has determined that a whole cell vaccine (WCV) made from killed unencapsulated pncumococcal cells, as well as purified antigens, can protect animals against colonization via CD4 + T Hl7 responses.
IPSCIO Record ID: 336296
Antigen shall mean (i) HPV antigens and/or (ii) HPV proteins and/or (iii) other physical forms based on such antigens, such as peptides and/or nucleic acid(s) (DNA, RNA) delivered in any form including recombinant vectors.
Vaccine Product shall mean an HPV Vaccine (x)covered in whole or in part by a Licensor Patent or an Licensee Patent which covers Licensee Special Technology and/or (y) which incorporates or is derived from the use of Licensor Technology and/or Licensee Special Technology.
Licensor Patents shall mean
5,298,418 – Cell line isolated from larval midgut tissue of Trichoplusia ni
5,300,435 – Trichoplusia ni cell line which supports replication of baculoviruses
5,437,951 – Self-assembling recombinant papillomavirus capsid proteins
Licensor Technology shall mean information, know-how and materials, including, but not limited to, pharmaceutical, chemical and biological products, technical and non-technical data and information (i) owned by Licensor and/or to which Licensor has a transferable interest on the Effective Date and/or at any time during the term of this Agreement and (ii) which relate to the field of L1 based HPV Vaccines and/or which arise from the Research Program, and in each case which are necessary or useful for the development, manufacture, use or sale of an HPV Vaccine.
Human papillomavirus (HPV) is the most common sexually transmitted infection (STI).
Many people with HPV don't develop any symptoms but can still infect others through sexual contact. Symptoms may include warts on the genitals or surrounding skin.
There's no cure for the virus and warts may go away on their own. Treatment focuses on removing the warts. A vaccine that prevents the HPV strains most likely to cause genital warts and cervical cancer is recommended for boys and girls.
IPSCIO Record ID: 345562
ChAdOx1 and ChAdOx2 are modified simian adenoviral vectors which deliver target antigens into cells to generate a specific immune response. These viruses were originally isolated from chimpanzees to avoid pre-existing immunity issues affecting the use of human adenovirus vectors.
IPSCIO Record ID: 328343
AIDS Vaccine means a vaccine which would prevent an infection by Human Immunodeficiency Virus (HIV-1) and/or clinical diseases caused by infection with HIV-1 in humans.
Influenza Vaccine means a vaccine which would prevent an infection and/or significant clinical diseases caused by any influenza virus in humans.
Licensed Product means a bulk or finished AIDS Vaccine or Influenza Vaccine, or other vaccine for the prevention of human infectious disease if licensed hereunder, which utilizes the Technology or technology which is developed by Licensor during and as a result of the Research Collaboration Program; provided, however, that if any such vaccine is also capable of being used for treatment of the same human infectious disease, then such therapeutic use of such vaccine shall also be considered a Licensed Product for purposes of the license being granted by Licensor to Licensee under this Agreement.
IPSCIO Record ID: 257474
The parties wish to further amend the Agreement to provide that Merck shall have rights to vaccine products for the treatment of patients infected with Human Immunodeficiency Virus and Hepatitis B Virus.